Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease

Cancer Immunology, Immunotherapy

Volumn 63, Issue 12, 2014, Pages 1341-1346

  Pedersen, Magnus ^a   Andersen, Rikke ^a   Nørgaard, Peter ^a   Jacobsen, Søren ^b   Thielsen, Peter ^a   thor Straten, Per ^a   Svane, Inge Marie ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

Immune therapy; Interleukin 2; Ipilimumab; Metastatic malignant melanoma; Systemic autoimmune disease

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; AZATHIOPRINE; B RAF KINASE; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 2; IPILIMUMAB; MESALAZINE; METHOTREXATE; OPIATE; PREDNISOLONE; STEROID; TEMOZOLOMIDE; MONOCLONAL ANTIBODY;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BEHCET DISEASE; BODY WEIGHT; BRAIN METASTASIS; BREAST METASTASIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER MORTALITY; CANCER PAIN; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SIZE; CANCER SURGERY; CASE REPORT; COLON RESECTION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONGENITAL NEVUS; CONTINUOUS INFUSION; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; ILEOSTOMY; INFLAMMATORY BREAST CANCER; KARNOFSKY PERFORMANCE STATUS; LIVER METASTASIS; LOSS OF APPETITE; LYMPH NODE METASTASIS; MALE; MENTAL STRESS; METASTATIC MELANOMA; MIDDLE AGED; MOUTH ULCER; MULTIMODALITY CANCER THERAPY; PERITONEUM METASTASIS; PRIMARY TUMOR; SIDE EFFECT; SKIN PRURITUS; STEREOTACTIC RADIOSURGERY; TREATMENT DURATION; TUMOR INVASION; ULCERATIVE COLITIS; AUTOIMMUNE DISEASES; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA; PATHOLOGY; PROCEDURES;

ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED;

EID: 84916205029     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1607-y     Document Type: Article

References (24)

1. Wolchok JD, Yang AS, Weber JS (2010) Immune regulatory antibodies: are they the next advance? Cancer J 16:311–317
2. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17:4550–4557
3. Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD, Clark JI, Curti B, Ernstoff MS, Gajewski T, Gonzalez R, Hyde LJ, Lawson D, Lotze M, Lutzky J, Margolin K, McDermott DF, Morton D, Pavlick A, Richards JM, Sharfman W, Sondak VK, Sosman J, Steel S, Tarhini A, Thompson JA, Titze J, Urba W, White R, Atkins MB (2013) The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 10:588–598
4. Waldmann TA (2006) The biology of Interleukin-2 and Interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6:595–601
5. Platanias LC (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 5:375–386
6. Schadendorf D, Algarra SM, Bastholt L, Cinat G, Dreno B, Eggermont AM, Espinosa E, Guo J, Hauschild A, Petrella T, Schachter J, Hersey P (2009) Immunotherapy of distant metastatic disease. Ann Oncol 20(Suppl 6):vi41–vi50
7. Keilholz U, Scheibenbogen C, Tilgen W, Bergmann L, Weidmann E, Seither E, Richter M, Brado B, Mitrou PS, Hunstein W (1993) Interferon-alpha and Interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials. Cancer 72:607–614
8. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM (2011) Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16:5–24
9. Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, Chin K, Canetta R, Humphrey R (2010) Development of Ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 37:533–546
10. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with Ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723
11. Schadendorf D, Hauschild A (2014) Melanoma in 2013: Melanoma–the run of success continues. Nat Rev Clin Oncol 11:75–76
12. Feakins RM (2013) Inflammatory bowel disease biopsies: updated British Society of Gastroenterology reporting guidelines. J Clin Pathol 66:1005–1026
13. Ford AC, Moayyedi P, Hanauer SB (2013) Ulcerative colitis. BMJ 346:f432
14. Mat C, Yurdakul S, Sevim A, Ozyazgan Y, Tuzun Y (2013) Behcet’s syndrome: facts and controversies. Clin Dermatol 31:352–361
15. Dalvi SR, Yildirim R, Yazici Y (2012) Behcet’s Syndrome. Drugs 72:2223–2241
16. Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Keller U, Klein C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von MR, Weder P, Wilhelm T, Goppner D, Dummer R, Heinzerling LM (2013) The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the Ipilimumab network. PLoS One 8:e53745
17. Slangen RM, van den Eertwegh AJ, van Bodegraven AA, de Boer NK (2013) Diarrhoea in a patient with metastatic melanoma: ipilimumab ileocolitis treated with infliximab. World J Gastrointest Pharmacol Ther 4:80–82
18. Walker LS, Sansom DM (2011) The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 11:852–863
19. Holmen N, Lundgren A, Lundin S, Bergin AM, Rudin A, Sjovall H, Ohman L (2006) Functional CD4 + CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity. Inflamm Bowel Dis 12:447–456
20. Weide B, Martens A, Zelba H, Stutz C, Derhovanessian E, Di Giacomo AM, Maio M, Sucker A, Schilling B, Schadendorf D, Buttner P, Garbe C, Pawelec G (2014) Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin Cancer Res 20:1601–1609
21. Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM, Caraco C, Curvietto M, Esposito A, Paone M, Palla M, Cavalcanti E, Sandomenico F, Petrillo A, Botti G, Fulciniti F, Palmieri G, Queirolo P, Marchetti P, Ferraresi V, Rinaldi G, Pistillo MP, Ciliberto G, Mozzillo N, Ascierto PA (2014) Immunological and biological changes during Ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother 63:675–683
22. Sugi-Ikai N, Nakazawa M, Nakamura S, Ohno S, Minami M (1998) Increased frequencies of Interleukin-2- and interferon-gamma-producing T cells in patients with active Behcet’s disease. Invest Ophthalmol Vis Sci 39:996–1004
23. Yalcindag FN, Uzun A (2012) Results of interferon alpha-2a therapy in patients with Behcet’s disease. J Ocul Pharmacol Ther 28:439–443
24. Shevach EM (2012) Application of IL-2 therapy to target T regulatory cell function. Trends Immunol 33:626–632